UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
| 13.42 | |
| 13.43 | |
| - | |
| 13.51 | |
| 13.001 | |
| 10.6001-20.7 | |
| 562 M | |
| 42 114 K | |
| 85 011 K | |
| -0.91 | |
| 1.125 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Conference Call and Webcast Scheduled for Thursday, August 10, 2023 at 10:00 AM ET PRINCETON, N.J., August 02, 2023--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to...
It’s been clear for a while now that the stock market is on an upward trajectory, buoyed by a resilient economy and retreating high inflation. The good news, according to John Stoltzfus, Chief Inves...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
